ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2105

Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1977

Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)

(1977–1995) Osteoarthritis – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 1895

Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2079

Comparative Analysis of Teledidactic and On-Campus Training in Musculoskeletal Ultrasound – the TELMUS Study

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 2008

Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2307

Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2219

Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2125

Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2097

Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2416

Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 2314

Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1974

Comparison of Gait Spatiotemporal Measures Between Patients with Insertional Achilles Tendinopathy or Midportion Achilles Tendinopathy

(1973–1976) Orthopedics, Low Back Pain, & Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 2083

Compiled Verbal Feedback as a Novel Mechanism for Faculty Feedback from Rheumatology Fellows-in-Training

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1818

Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S

(1796–1826) Epidemiology & Public Health Poster III

«Previous Page
1
…
8
9
10
11
12
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.